Hematology and Oncology, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Hematology, Oncology and Transplantation, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Expert Rev Anticancer Ther. 2022 Jul;22(7):671-679. doi: 10.1080/14737140.2022.2081154. Epub 2022 May 26.
In May 2020, the approval of rucaparib - a poly-ADP-ribose polymerase (PARP) inhibitor - in the USA marked the arrival of a new class of targeted therapeutics for a subset of metastatic castration-resistant prostate cancer patients whose tumors harbor germline or somatic gene alterations. It has now become critical for physicians to be aware of the role and nuances of management of PARP inhibitor therapies in prostate cancer.
We focus on rucaparib's pharmacology, key clinical trials that support its current indication, the competitive landscape, and our considerations for management of adverse events. We also review the ongoing clinical trials that may expand its utility in prostate cancer in our expert opinion. Finally, we discuss the opportunities that exist for further development of this class of targeted agents in prostate cancer.
We believe that the time has come to develop functional assays of HRR proficiency or deficiency in order to better guide PARP inhibitor selection for patients with prostate cancer and beyond.
2020 年 5 月，鲁卡帕利（rucaparib）——一种聚 ADP-核糖聚合酶（PARP）抑制剂——在美国获得批准，标志着一类新的靶向治疗药物的出现，适用于其肿瘤携带种系或体细胞基因改变的转移性去势抵抗性前列腺癌患者亚群。现在，医生们必须意识到 PARP 抑制剂在前列腺癌中的作用和管理上的细微差别。
我们专注于鲁卡帕利的药理学、支持其当前适应证的关键临床试验、竞争格局以及我们对不良反应管理的考虑。我们还回顾了可能在我们的专家意见中扩大其在前列腺癌中的应用的正在进行的临床试验。最后，我们讨论了在前列腺癌中进一步开发这类靶向药物的机会。
我们认为，现在是时候开发 HRR 功能检测来评估其是否存在缺陷，以便更好地指导 PARP 抑制剂在前列腺癌及其他疾病中的选择。
